Interleukin-3 biosimilar- Cangene

Drug Profile

Interleukin-3 biosimilar- Cangene

Alternative Names: Allevorin; SDZ 215134

Latest Information Update: 08 Oct 2002

Price : $50

At a glance

  • Originator Cangene Corporation
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 3 stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Haematological disorders; Haematological malignancies; Preleukaemia

Most Recent Events

  • 08 Oct 2002 Discontinued - Preclinical for Cancer in Canada (unspecified route)
  • 08 Oct 2002 Discontinued - Preregistration for Cancer in Italy (IV)
  • 08 Oct 2002 Discontinued - Clinical-Phase-Unknown for Haematological malignancies in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top